FDA Approves First Targeted Drug To Treat HER2-Low Breast Cancer: Trastuzumab Deruxtecan (T-DXd)

HER2-Positive Breast Cancer: From Diagnosis and Treatment to Monitoring

HER2-positive breast cancer vaccine passes 20 years of human trials

🚨Exciting new press release in HR /HER2- breast cancer! Current standard of care for the past 20 years in early stage HR breast cancer has been endocrine therapy with tamoxifen or an aromatase inhibitor. In metastatic breast cancer, we are increasingly using oral SERDs, which are selective estrogen receptor degraders. SERDs work by binding to the estrogen receptor, which causes a conformational change that leads to the receptor’s degradation through the proteasome pathway. There are several SER

Stage 4 (IV) Breast Cancer: Survival Rates, Treatment & Prognosis

Abigail's Stage 4 Metastatic Breast Cancer Story